Outset Medical will announce Q1 2025 financial results on May 7, followed by a conference call with executives.
Quiver AI Summary
Outset Medical, Inc. announced that it will release its financial results for the first quarter of 2025 on May 7, 2025, after market close. The company's Chair and CEO, Leslie Trigg, along with CFO Nabeel Ahmed, will host a conference call at 2:00 p.m. Pacific time to discuss these results. Participants can register online for the call to receive dial-in information, and a live and archived webcast will be available on the company's website. Outset Medical is known for its innovative Tablo® Hemodialysis System, designed to reduce dialysis costs and complexity, offering a comprehensive solution for delivering care in various settings.
Potential Positives
- Outset Medical is set to release its first-quarter 2025 financial results, indicating transparency and engagement with investors.
- The upcoming conference call led by the CEO and CFO presents an opportunity for direct communication with shareholders, reflecting the company's commitment to investor relations.
- The announcement highlights the innovative nature of Outset's Tablo® Hemodialysis System, which is positioned as a groundbreaking solution in dialysis technology.
- The technology's ability to simplify dialysis processes and enhance patient care demonstrates Outset's potential for growth and competitive advantage in the medical technology market.
Potential Negatives
- Announcement of upcoming financial results may indicate potential investor concern if prior performance was underwhelming, leading to increased scrutiny during the call.
- Lack of detailed financial context or prior performance data in the release could raise questions about the company's financial health and growth trajectory.
- Timing of the financial results announcement and conference call may suggest limited communication strategy if it's perceived as an attempt to control the narrative around financial performance.
FAQ
When will Outset Medical announce Q1 2025 financial results?
Outset Medical will announce financial results for Q1 2025 after the close of trading on May 7, 2025.
What time is the conference call for Q1 2025 results?
The conference call will begin at 2:00 p.m. Pacific time on May 7, 2025.
How can I join the Outset Medical conference call?
To join, you must register online to receive dial-in numbers and a unique pin for the call.
Where can I find the webcast of the conference call?
A live and archived webcast will be available in the “Investors” section of Outset's website.
What is the Tablo® Hemodialysis System?
The Tablo® Hemodialysis System is an innovative technology designed to simplify dialysis for patients and healthcare providers.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OM Insider Trading Activity
$OM insiders have traded $OM stock on the open market 28 times in the past 6 months. Of those trades, 0 have been purchases and 28 have been sales.
Here’s a breakdown of recent trading of $OM stock by insiders over the last 6 months:
- LESLIE TRIGG (Chair and CEO) has made 0 purchases and 6 sales selling 114,335 shares for an estimated $96,811.
- NABEEL AHMED (Chief Financial Officer) has made 0 purchases and 7 sales selling 78,034 shares for an estimated $64,482.
- JOHN L. BROTTEM (General Counsel) has made 0 purchases and 7 sales selling 64,342 shares for an estimated $53,063.
- MARC NASH (SVP Operations and R&D) has made 0 purchases and 8 sales selling 44,531 shares for an estimated $36,548.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OM Hedge Fund Activity
We have seen 22 institutional investors add shares of $OM stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERIPRISE FINANCIAL INC removed 1,810,234 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,009,359
- MUBADALA INVESTMENT CO PJSC removed 1,440,601 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,599,067
- FMR LLC removed 1,102,563 shares (-23.1%) from their portfolio in Q4 2024, for an estimated $1,223,844
- RENAISSANCE TECHNOLOGIES LLC added 632,574 shares (+1167.7%) to their portfolio in Q4 2024, for an estimated $702,157
- MILLENNIUM MANAGEMENT LLC removed 495,174 shares (-26.2%) from their portfolio in Q4 2024, for an estimated $549,643
- NORGES BANK removed 461,400 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $512,154
- D. E. SHAW & CO., INC. removed 428,636 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $475,785
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN JOSE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter 2025 after the close of trading on Wednesday, May 7, 2025.
On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results.
Conference Call Details
The conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on Wednesday, May 7, 2025. Those interested in joining the conference call may do so by
registering online
. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived webcast of the event will be available on the “Investors” section of the Outset website at
https://investors.outsetmedical.com/
.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo
®
Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Contact
Jim Mazzola
Investor Relations
[email protected]
